|
Both have coverage initiated by Merriman, both a "buy" rating. Both have proven their biotechnology in trials, both could get bought out at high premiums sometime in the near future. What are they? NVAX & YMI
Rating :
 (No ratings) |
 |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
0.08